Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Summary

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Alopecia Areata

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

12 to 17 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Sun Pharmaceutical Industries, Inc.

Last updated on ClinicalTrials.gov

January 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites